OSLO, NORWAY – Curida Holding AS (“Curida”) has announced a significant growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare private equity firm together with existing shareholders, Canica, Investinor, Klaveness Marine and Farvatn Private Equity. This investment will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position. The total investment is in the range of 230M Nok – 260M Nok, but Investment details has not been officially disclosed.

In conjunction with Signet’s investment, Signet is joining the Board of Directors, and Ole J. Dahlberg has been appointed as Chairman of the Board. Dahlberg stated, “We are very pleased to welcome Signet in as a significant shareholder in Curida. Signet brings strong relevant industry experience and a track record of CDMO investing. We are excited by the opportunity to further accelerate growth and improve products for our pharma and biotech customers in their work to deliver medicines and therapeutics to benefit patients. On behalf of the board, I want to thank Per Thoresen, who has been acting Chairman and for his valuable contributions to Curida over the past 9 years.” The Board has appointed Anders Larsson, the company’s Chief Operating Officer, as CEO, effective May 1st 2024. Larsson comes with extensive experience in management, operations, and strategic development from the pharma industry. His former roles include CEO in Boots Pharmacies/Alliance Healthcare in Norway (Cencora). In addition, Larsson has held multiple management roles in the food & beverage industry with Orkla and Carlsberg. Larsson holds a MSc in Chemical Engineering from Chalmers University and Imperial College and a BSc in finance from Gothenburg University.

About Curida Group
Curida was established in 2015 and is headquartered in Oslo, Norway, Curida Holding includes Curida AS, Curida Diatec AS and Ås Produksjonslab AS, and is an integrated Contract Development and Manufacturing Organization (“CDMO”) and offers contract development and manufacturing solutions to European pharmaceutical and biotech companies globally. Curida focuses on aseptic and non-aseptic liquid manufacturing and specializes in blow-fill-seal (“BFS”) and nasal spray technologies to serve the Small Molecules pharmaceutical and medical device market. For biologics, Curida offers upstream – and downstream processing of monoclonal antibodies for in-vitro diagnostics (“IVD”). Curida’s customer base ranges from small to medium-sized pharmaceutical and biotech companies, delivering solutions in drug development and GMP manufacturing globally. For more information, visit www.curida.no

About Signet Healthcare Partners
Headquartered in New York, NY, Signet is an established provider of growth capital to innovative healthcare companies. SIGNET invests in commercial-stage healthcare companies that are revenue generating or preparing for commercial launch. The firm invests primarily in pharmaceutical and medical device companies. As an active investor, Signet partners closely with its companies to build their value including facilitating activities between portfolio companies. During Signet’s 25-year history, the firm has developed a strong reputation and track record of successful healthcare investments. Signet has raised funds with total capital commitments of over $600 million and has invested in more than 55 companies. For more information, visit www.signethealthcarepartners.com.

Curida Holding AS
Ole J. Dahlberg
Chairman of the Board

Anders Larsson